Stoke Therapeutics, Inc. $STOK Shares Sold by Baker BROS. Advisors LP

Baker BROS. Advisors LP trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 28.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,336,697 shares of the company’s stock after selling 1,297,141 shares during the quarter. Stoke Therapeutics makes up approximately 0.6% of Baker BROS. Advisors LP’s investment portfolio, making the stock its 25th largest position. Baker BROS. Advisors LP owned approximately 5.84% of Stoke Therapeutics worth $105,907,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in STOK. State Street Corp raised its stake in shares of Stoke Therapeutics by 75.2% during the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after buying an additional 1,072,176 shares during the period. Corient Private Wealth LLC acquired a new position in shares of Stoke Therapeutics during the 2nd quarter worth approximately $7,489,000. BVF Inc. IL raised its stake in shares of Stoke Therapeutics by 36.7% during the 4th quarter. BVF Inc. IL now owns 2,265,674 shares of the company’s stock worth $71,912,000 after buying an additional 608,578 shares during the period. Wellington Management Group LLP raised its stake in shares of Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock worth $17,337,000 after buying an additional 600,687 shares during the period. Finally, Polar Capital Holdings Plc raised its stake in shares of Stoke Therapeutics by 49.8% during the 3rd quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after buying an additional 439,824 shares during the period.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $30.26 on Thursday. Stoke Therapeutics, Inc. has a one year low of $11.17 and a one year high of $40.22. The stock has a market capitalization of $1.88 billion, a price-to-earnings ratio of -10.77 and a beta of 1.17. The stock has a 50 day moving average price of $32.07 and a 200 day moving average price of $32.35.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.01. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%.The firm had revenue of $6.23 million during the quarter, compared to analysts’ expectations of $6.48 million. On average, analysts predict that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. BTIG Research reaffirmed a “buy” rating and set a $39.00 target price on shares of Stoke Therapeutics in a research note on Monday, May 11th. Wedbush upped their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 17th. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. Wall Street Zen cut Stoke Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Stoke Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

Insider Transactions at Stoke Therapeutics

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $30.58, for a total value of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This represents a 4.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.50% of the stock is currently owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.